| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | PROCESS FOR THE PREPARATION OF FINASTERIDE FORM I | EP04743251.3 | 2004-07-05 | EP1651661B1 | 2008-08-27 | KANKAN, Rajendra, Narayanrao A-3/5, NBD Society; RAO, Dharmaraj, Ramachandra 4/403 Garden Enclave |
| A process of preparing finasteride Form (I), which process comprises dissolving finasteride in a solvent, replacing the solvent partially or substantially completely with a nonsolvent and thereafter isolating finasteride Form (I). There is also provided finasteride Form (I) prepared in accordance with the present invention, and the therapeutic use thereof in the inhibition of 5-alpha reductase, and pharmaceutical compositions containing the same. | ||||||
| 22 | ANDROGEN SYNTHESIS INHIBITORS | EP98903769.2 | 1998-02-05 | EP1019060B1 | 2007-08-01 | BRODIE, Angela; LING, Yangzhi |
| This invention relates to novel inhibitors of androgen synthesis that are useful in the treatment of prostate cancer and benign prostatic hypertrophy. The present invention also provides methods of synthesizing these novel compounds, pharmaceutical compositions containing these novel compounds, and methods of treating prostate cancer and benign prostatic hypertrophy using the androgen synthesis inhibitors of the present invention. | ||||||
| 23 | Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it | EP06019093.1 | 2001-06-19 | EP1790653A2 | 2007-05-30 | Reddy, M. Satyanarayana; Rajan, S. T.; Rao, M. V. N.; Vyas, K.; Reddy, S. Visnuvardhana; Rekha, K. Shashi |
The present invention relates to a novel polymorphic form of 17-β-(N-Ter.Butyl Carbamoyl)-4-aza-5-α-androst-1-en-one (Finesteride) and processes for preparing the form.
|
||||||
| 24 | STEROID 3-O-SULPHAMATE DERIVATIVES AS INHIBITORS OF OESTRONE SULPHATASE | EP98957031.2 | 1998-12-03 | EP1051177B1 | 2006-04-19 | REED, Michael, John; POTTER, Barry, Victor, Lloyd, University of Bath |
| A sulphamate compound suitable for use as an inhibitor of oestrone sulphatase (E.C.3.1.6.2) is described. The compound is a polycyclic compound comprising at least two ring components, wherein the polycyclic compound comprises at least one sulphamate group attached to at least one of the ring components, and wherein at least one of the ring components of the polycyclic structure is a heterocyclic ring. | ||||||
| 25 | PROCESS FOR OBTAINING 17BETA-(N-TERC-BUTYLCARBAMOYL)-3-ONE-4-AZA-STEROIDS | EP00940431.0 | 2000-07-05 | EP1116725B1 | 2004-01-14 | SILVA GUISASOLA, Luis Octavio Parque Tecnologico; BLANCO FERNANDEZ, Cristina Parque Tecnologico; LORENTE BONDE-LARSEN, Antonio Parque Tecnologico; MARTIN JUAREZ, Jorge Parque Tecnologico |
| 26 | STEROID 3-O-SULPHAMATE DERIVATIVES AS INHIBITORS OF OESTRONE SULPHATASE | EP98957031.2 | 1998-12-03 | EP1051177A1 | 2000-11-15 | REED, Michael, John; POTTER, Barry, Victor, Lloyd,University of Bath |
| A sulphamate compound suitable for use as an inhibitor of oestrone sulphatase (E.C.3.1.6.2) is described. The compound is a polycyclic compound comprising at least two ring components, wherein the polycyclic compound comprises at least one sulphamate group attached to at least one of the ring components, and wherein at least one of the ring components of the polycyclic structure is a heterocyclic ring. | ||||||
| 27 | $i(SPECIFIC) STEADY-STATE R-TYPE Ca?2+ CHANNEL BLOCKERS AND USE THEREOF | EP98944936.8 | 1998-09-28 | EP1028734A1 | 2000-08-23 | BKAILY, Ghassan; D'ORLEANS-JUSTE, Pedro; CALIXTO, Joao, B.; YUNES, Rosendo, A. |
| The present invention relates to Ca2+ channel blockers and more particularly to the R-type Ca2+ channel blockers. More specifically, the invention relates to Ca2+ channel blockers activity of Mandevilla velutina and Mandevilla illustris. The present invention further concerns saponin-like compounds isolated from Mandevilla species. The present invention also relates to the treatment of several pathologies that involve the nifedipine-insensitive but isradipine sensitive steady-state R-type Ca2+ channel and the use of steady-state R-type Ca2+ channel blockers in the treatment of these pathologies. | ||||||
| 28 | Androgen synthesis inhibitors | JP53301598 | 1998-02-05 | JP5043250B2 | 2012-10-10 | ブロディー，アンジェラ; リン，ヤンツィー |
| 29 | Production method of 2,5-bis (trifluoromethyl) nitrobenzene | JP2003562071 | 2003-01-24 | JP4474921B2 | 2010-06-09 | 環 清水 |
| 30 | 過酸化水素およびタングステン触媒を用いたアルコールの酸化反応 | JP2006513545 | 2005-05-12 | JPWO2005110958A1 | 2008-03-21 | 壮真 樋田; 享三 河田; 幹雄 樺木 |
| 過酸化水素およびタングステン触媒を含有する混合試薬を用い、アミド系溶媒中でアルコールを酸化する方法。 | ||||||
| 31 | Steroid 3-o- sulfamate derivatives as inhibitors of estrone sulfatase | JP2000522920 | 1998-12-03 | JP3820349B2 | 2006-09-13 | バリー ビクター ロイド ポッター，; マイケル ジョン リード， |
| 32 | ２，５−ビス（トリフルオロメチル）ニトロベンゼンの製造方法 | JP2003562071 | 2003-01-24 | JPWO2003062187A1 | 2005-05-19 | 清水 環; 環 清水 |
| 工業的に入手容易な原料から、反応操作が簡便で取扱いの容易な物質を用いて、短い工程で、かつ温和な反応条件で、2,5−ビス(トリフルオロメチル)ニトロベンゼンを高収率で製造できる方法を提供する。硫酸濃度が91〜100質量%の硫酸、および、三酸化硫黄濃度が0質量%超でありかつ20質量%以下の発煙硫酸から選ばれる酸を必須とする溶媒中で、1,4−ビス(トリフルオロメチル)ベンゼンを硝酸を用いてニトロ化する。 | ||||||
| 33 | 17β (N-TERC-BUTYLCARBAMOYL) method of manufacturing a -3-ONE-4-AZA-STEROID | JP2001507858 | 2000-07-05 | JP2003503507A | 2003-01-28 | ギサソラ，ルイス オクタビオ シルバ; フェルナンデス，クリスティーナ ブランコ; フワレス，ホルヘ マルティン; ボンデ−ラルセン，アントニオ ロレンテ |
| (57)【要約】 17β(N-terc-butylcarbamoyl)-3-one-4-aza-steroid（I）は有機溶剤中の17β(alcoxycarbonyl)-3-one-4-aza-steroidとリチウムterc-butylamideより獲得できる。 finasterideの如く(I)の化学物質は5α-reductoseの抑制剤として使用でき、前立腺過形成や脱毛症治療に適している。 | ||||||
| 34 | Androgen synthesis inhibitors | JP53301598 | 1998-02-05 | JP2001510471A | 2001-07-31 | ブロディー，アンジェラ; リン，ヤンツィー |
| (57)【要約】 本発明は、前立腺癌および良性前立腺肥大症の治療において有用なアンドロゲン合成の新規なインヒビターに関する。 本発明は、また、それらの新規な化合物を合成する方法、これらの新規な化合物を含有する医薬組成物、および本発明のアンドロゲン合成インヒビターを使用して前立腺癌および良性前立腺肥大症を治療する方法を提供する。 | ||||||
| 35 | JPS4935626B1 - | JP2692172 | 1972-03-16 | JPS4935626B1 | 1974-09-25 | |
| 36 | 피나스테라이드와 펩타이드의 결합체 | KR1020187026417 | 2016-05-20 | KR1020180112003A | 2018-10-11 | |
| 본발명은탈모방지용조성물에관한것으로서, 보다상세하게는피나스테라이드와펩타이드가공유결합으로연결된구조를갖는화합물및 이를포함하는탈모방지또는발모촉진용약학적조성물또는화장료조성물에관한것이다. 본발명의피나스테라이드와펩타이드가공유결합으로연결된구조를갖는화합물은탈모개선, 발모촉진, 세포성장촉진등과같은생리활성이우수할뿐만아니라물에서의안정성및 피부투과율이우수하므로, 탈모방지및 발모촉진용조성물로서유용하게사용될수 있다. | ||||||
| 37 | 17-β-(엔-티-부틸카르바모일)-4-아자-5-α-안드로스트-1-엔-3-온의 신규의다형태 및 그 제조방법 | KR1020037003413 | 2001-06-19 | KR1020030029947A | 2003-04-16 | 레디,엠.,사티아나라야나; 라잔,에스.,티.; 라오,엠.,브이.,엔.,브라흐메쉬와라; 비아스,케이; 레디,에스.,비쉬누바르드하나; 레크하,케이.,샤시 |
| 본 발명은 식 (1)의 17-β-(Nt-부틸 카르바모일)-4-아자-5-α-안드로스트-1-엔-3-온의 신규의 다형태 및 그 제조방법에 관한 것이다. (Ⅰ) | ||||||
| 38 | Limonin extraction method | US15302983 | 2015-04-30 | US09896477B2 | 2018-02-20 | Hui Ni; Huinong Cai; Yuanfan Yang; Qiufen Gao; Feng Chen; Xiping Du; Gaoling Huang; Ling Wu; Anfeng Xiao |
| A limonin extraction method, comprising the following steps: step one, raw material extracting or juicing: directly soaking raw material in water or using a presser to directly juice the raw material to obtain the extract; step two, adding salt and adjusting pH: adding a sulfate solid material or saturated sulfate solution to the extract; adjusting pH to 3-7; step three, heating and preserving heat: heating to 20° C.-100° C. and keeping at the temperature for 10 minutes-110 minutes; step four, centrifuging: centrifuging for 10 minutes at a rotational speed of 2500×g, and obtaining limonin precipitation. Compared with a traditional method, the raw material in the present invention can directly use the extract liquid or juicing liquid without drying, and recover most limonin in water using a precipitation method without complicated apparatus, and is easy to operate and has a low process cost. | ||||||
| 39 | LIMONIN EXTRACTION METHOD | US15302983 | 2015-04-30 | US20170029460A1 | 2017-02-02 | Hui NI; Huinong CAI; Yuanfan YANG; Qiufen GAO; Feng CHEN; Xiping DU; Gaoling HUANG; Ling WU; Anfeng XIAO |
| A limonin extraction method, comprising the following steps: step one, raw material extracting or juicing: directly soaking raw material in water or using a presser to directly juice the raw material to obtain the extract; step two, adding salt and adjusting pH: adding a sulfate solid material or saturated sulfate solution to the extract; adjusting pH to 3-7; step three, heating and preserving heat: heating to 20° C.-100° C. and keeping at the temperature for 10 minutes-110 minutes; step four, centrifuging: centrifuging for 10 minutes at a rotational speed of 2500×g, and obtaining limonin precipitation. Compared with a traditional method, the raw material in the present invention can directly use the extract liquid or juicing liquid without drying, and recover most limonin in water using a precipitation method without complicated apparatus, and is easy to operate and has a low process cost. | ||||||
| 40 | Process for obtaining the polymorphic form I of finasteride | US11119027 | 2005-04-29 | US07795435B2 | 2010-09-14 | Luis Octavio Silva Guisasola; Mario Laderas Muñoz; Jorge Martin Juarez |
| The process includes the steps of (i) dissolving finasteride in a substantially anhydrous organic solvent selected among n-butyl acetate, iso-butyl acetate, sec-butyl acetate, tert-butyl acetate, C5 alkyl acetate and mixtures thereof, at a temperature equal to or lower than the boiling point of said organic solvent; (ii) slowly cooling said finasteride solution to a cooling temperature determined on the basis of the chosen solvent; (iii) maintaining the resulting suspension at the cooling temperature for a period of time equal to or less than 16 hours; and (iv) recovering the resulting solid phase containing Form I of finasteride, for example by means of filtration, and removing the solvent, for example by means of drying said crystals. The process allows for obtaining the Form I of finasteride only and in a pure form. | ||||||
QQ群二维码
意见反馈
意见反馈